Edgar Filing: AMICUS THERAPEUTICS INC

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Weinhoff Gregory M

2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS INC [FOLD]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O CHL MEDICAL PARTNERS, 1055 WASHINGTON BLVD.

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2007

(Street)

STAMFORD, CT 06901

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2007		C		1,975,223	A	⁽¹⁾	2,108,555	I	By Partnership ⁽⁴⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series A Convertible Preferred Stock

⁽¹⁾

06/05/2007

83,278

04/15/2002

⁽¹⁾

Common Stock

83,278

$ 0

By CHL Medical Partners II, L.P. ⁽²⁾

Series A Convertible Preferred Stock

⁽¹⁾

06/05/2007

5,611

04/15/2002

⁽¹⁾

Common Stock

5,611

$ 0

By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Series B Convertible Preferred Stock

⁽¹⁾

06/05/2007

734,803

05/04/2004

⁽¹⁾

Common Stock

734,803

$ 0

By CHL Medical Partners II, L.P. ⁽²⁾

Series B Convertible Preferred Stock

⁽¹⁾

06/05/2007

49,509

05/04/2004

⁽¹⁾

Common Stock

49,509

$ 0

By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Series B Convertible Preferred Stock

⁽¹⁾

06/05/2007

11,182

04/18/2006

⁽¹⁾

Common Stock

11,182

$ 0

By CHL Medical Partners II, L.P. ⁽²⁾

Series B Convertible Preferred Stock

⁽¹⁾

06/05/2007

753

04/18/2006

⁽¹⁾

Common Stock

753

$ 0

By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Series C Convertible Preferred Stock

⁽¹⁾

06/05/2007

247,850

08/16/2005

⁽¹⁾

Common Stock

247,850

$ 0

By CHL Medical Partners II, L.P. ⁽²⁾

Series C Convertible Preferred Stock

⁽¹⁾

06/05/2007

16,669

08/16/2005

⁽¹⁾

Common Stock

16,699

$ 0

By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Series C Convertible Preferred Stock

⁽¹⁾

06/05/2007

247,850

04/17/2006

⁽¹⁾

Common Stock

247,850

$ 0

By CHL Medical Partners II, L.P. ⁽²⁾

Series C Convertible Preferred Stock

⁽¹⁾

06/05/2007

16,669

04/17/2006

⁽¹⁾

Common Stock

16,699

$ 0

By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Series D Convertible Preferred Stock

⁽¹⁾

06/05/2007

96,233

09/13/2006

⁽¹⁾

Common Stock

96,233

$ 0

By CHL Medical Partners II, L.P. ⁽²⁾

Series D Convertible Preferred Stock

⁽¹⁾

06/05/2007

6,484

09/13/2006

⁽¹⁾

Common Stock

6,484

$ 0

By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Series D Convertible Preferred Stock

⁽¹⁾

06/05/2007

96,223

03/09/2007

⁽¹⁾

Common Stock

96,233

$ 0

By CHL Medical Partners II, L.P. ⁽²⁾

Series D Convertible Preferred Stock

⁽¹⁾

06/05/2007

6,484

03/09/2007

⁽¹⁾

Common Stock

6,484

$ 0

By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Series A Convertible Preferred Stock

⁽¹⁾

06/05/2007

333,111

07/15/2002

⁽¹⁾

Common Stock

333,111

$ 0

By CHL Medical Partners II, L.P. ⁽²⁾

Series A Convertible Preferred Stock

⁽¹⁾

06/05/2007

22,444

07/15/2002

⁽¹⁾

Common Stock

22,444

$ 0

By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Weinhoff Gregory M C/O CHL MEDICAL PARTNERS 1055 WASHINGTON BLVD. STAMFORD, CT 06901	X

Signatures

/s/ Gregory M. Weinhoff		06/06/2007
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Each of the Series A Convertible Preferred Stock, the Series B Convertible Preferred Stock, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock automatically converted into Amicus Therapeutics, Inc. common stock on a one-for-one basis upon the closing of Amicus Therapeutics, Inc.'s initial public offering on June 5, 2007
(2)	The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.
(3)	The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II Side Fund, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II Side Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.
(4)	Consists of 1,975,456 shares held by CHL Medical Partner II, L.P. and 133,099 shares held by CHL Medical Partners II Side Fund, L.P. The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II, L.P. and CHL Medical Partners II Side Fund, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II, L.P. and CHL Medical Partners II Side Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.